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Genome-wide association study of breast cancer in
Latinas identifies novel protective variants on 6q25
Laura Fejerman1, Nasim Ahmadiyeh2, Donglei Hu1, Scott Huntsman1, Kenneth B. Beckman3,
Jennifer L. Caswell1, Karen Tsung2, Esther M. John4,5, Gabriela Torres-Mejia6, Luis Carvajal-Carmona7,8,
Marı´a Magdalena Echeverry7, Anna Marie D. Tuazon7, Carolina Ramirez8, COLUMBUS Consortiumw,
Christopher R. Gignoux9, Celeste Eng10, Esteban Gonzalez-Burchard10, Brian Henderson11,
Loic Le Marchand12, Charles Kooperberg13, Lifang Hou14, Ilir Agalliu15, Peter Kraft16, Sara Lindstro¨m16,
Eliseo J. Perez-Stable1, Christopher A. Haiman11 & Elad Ziv1
The genetic contributions to breast cancer development among Latinas are not well under-
stood. Here we carry out a genome-wide association study of breast cancer in Latinas and
identify a genome-wide significant risk variant, located 50 of the Estrogen Receptor 1 gene
(ESR1; 6q25 region). The minor allele for this variant is strongly protective (rs140068132:
odds ratio (OR) 0.60, 95% confidence interval (CI) 0.53–0.67, P¼9 10 18), originates
from Indigenous Americans and is uncorrelated with previously reported risk variants at
6q25. The association is stronger for oestrogen receptor-negative disease (OR 0.34, 95% CI
0.21–0.54) than oestrogen receptor-positive disease (OR 0.63, 95% CI 0.49–0.80;
P heterogeneity¼0.01) and is also associated with mammographic breast density, a strong
risk factor for breast cancer (P¼0.001). rs140068132 is located within several transcription
factor-binding sites and electrophoretic mobility shift assays with MCF-7 nuclear protein
demonstrate differential binding of the G/A alleles at this locus. These results highlight the
importance of conducting research in diverse populations.
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B
reast cancer incidence varies substantially across racial and
ethnic groups in the United States. The age-adjusted
incidence of breast cancer in US European Americans
and African Americans is 133.4 and 121.4 (per 100,000),
respectively, whereas US women of Latin American origin have
an incidence of 90.8 (ref. 1). Among Latina women, those with a
high proportion of Indigenous American ancestry are at a lower
risk of developing breast cancer2,3. This association could result
from the correlation between genetic ancestry and environmental
risk factors4, as well as genetics5. We have previously used
admixture mapping for breast cancer in Latinas and identified
6q25 as a locus at which ancestry is associated with breast
cancer5. Indigenous American ancestry at 6q25 is associated with
protection from breast cancer, suggesting the association with
global ancestry, could, at least in part, be because of genetic
variants at that locus.
Since 2007, breast cancer genome-wide association studies
(GWAS) have identified B80 loci with small to moderate effects
on risk (odds ratios (ORs) ranging from 1.05 go 1.53)6–28, with
the vast majority of these studies limited to women of European
ancestry, although GWAS has also been applied to populations of
Asian20,25–28 and African ancestry10,11. GWAS of breast cancer
in Latinas have not yet been published and may lead to the
discovery of new disease-associated variants and to improved
understanding of the genetic basis for health disparities, as
recently demonstrated for type 2 diabetes29. Here we use a GWAS
approach to find breast cancer risk variants in Latinas using data
from two studies2,5. We report the discovery of a genome-wide
significant breast cancer-protective variant of Indigenous
American origin (rs140068132), located 50 of the Estrogen
Receptor 1 gene (ESR1; 6q25 region).
Results
Discovery GWAS and replication. We initially performed a
GWAS of Latina women from the San Francisco Bay Area
including 977 cases and 722 controls, from the San Francisco Bay
Area Breast Cancer Study (SFBCS), the Northern California site
of the Breast Cancer Family Registry (NC-BCFR) and the
Genetics of Asthma in Latino Americans (GALA1, controls). We
also conducted a GWAS of 520 cases and 2,491 controls from the
Multiethnic Cohort (MEC). After imputation, the analysis of
the San Francisco study, which used an Affymetrix 6.0 array,
included 7,402,011 markers and the MEC, which used a combi-
nation of Illumina 1 and 2.5M arrays, included 9,031,188
markers.
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Figure 1 | Manhattan plot of GWAS for breast cancer in 1,497 Latina cases and 3,213 controls. On the x axis are genomic positions by chromosome.
On the y axis are the negative log10 P values for the association between the genetic variants and breast cancer risk. LMO4, LIM domain only 4;
MARCH4, membrane-associated ring finger (C3HC4) 4, E3 ubiquitin protein ligase; PDZD2, PDZ domain containing 2; ESR1, oestrogen receptor 1;
PSMA1, proteasome (prosome, macropain) subunit, alpha type, 1; TOX3, TOX high-mobility group box family member 3; RALY, RALY heterogeneous
nuclear ribonucleoprotein.
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We performed a meta-analysis of 7,229,558 markers that
overlapped between both data sets. In this meta-analysis that
included 1,497 cases and 3,213 controls, only variant rs4784227,
located at 30 of the TOX3 gene, a previously reported breast
cancer risk locus at 16q12.1 (ref. 28), achieved genome-wide
significance (Po5 10 8; T allele OR: 1.38 (95% CI: 1.24–1.54),
P¼ 3 10 9; P heterogeneity¼ 0.24). The strongest associated
variant outside the TOX3 region was variant rs147157845, located
B50 kb upstream of the ESR1 gene within a second known breast
cancer risk locus at 6q25 (OR: 0.59 (95% CI: 0.50–0.71),
P¼ 1.5 10 7; P heterogeneity¼ 0.47; imputation information
co-efficient¼ 0.92; Fig. 1). The quantile–quantile (Q–Q) plot and
the corresponding genomic inflation factor showed that adjust-
ment by the first 10 principal components dealt appropriately
with issues of population structure (l¼ 1.05; Fig. 2).
We selected 14 single-nucleotide polymorphisms (SNPs) with
Po9 10 7 for replication testing in an independent sample of
977 cases and 1,158 controls from a population-based breast
cancer study in Mexico30, of which nine were successfully
genotyped using Sequenom iPLEX assays. Two SNPs located
within the 6q25 region (rs147157845 and rs140068132) showed
highly statistically significant associations with effect sizes
similar to those in the discovery phase (Table 1). None of the
other SNPs were associated with breast cancer risk (Po0.05) in
the replication sample (Supplementary Table 1). Variants
rs147157845 (Chr6: position 151971376, allele frequencies in
US Latinas: C: 0.91, A: 0.09) and rs140068132 (Chr6: position
151954834, allele frequencies: A: 0.91, G: 0.09) are 16.5 kb apart
and are in strong linkage disequilibrium (LD; r2¼ 0.97). For
further validation, we tested the association of the rs140068132/
rs147157845 SNPs with breast cancer risk in a sample of 546
Colombian women with breast cancer and 440 Colombian
women without breast cancer, which also showed a strong
association, and in Latinas from the Women’s Health Initiative
(WHI) SHARe Study (120 cases and 3,373 controls), which
replicated both the magnitude and direction of the associations
(Table 1).
Fine mapping at 6q25 region and association with ancestry.
The rs140068132/rs147157845 SNPs are relatively common in
Latin American populations (5% in Puerto Ricans, 10% in
Colombians and 14% in Mexicans from the 1KGP) but are absent
in Europeans and Africans, and they have a very low frequency in
East Asians (Supplementary Table 2). Neither these variants nor
any correlated SNPs in Latinos were found to be in LD with the
index variants in the region previously reported in Asians and
Europeans12,18,31 (Fig. 3; Supplementary Fig. 1). In addition, none
of the previously reported variants at 6q25 showed genome-wide
statistically significant associations in the Latinas (Supplementary
Table 3). One GWAS-identified variant at 6q25 (rs9383938) had
an associated P value of 0.03 in the Latinas and the direction of
the OR was concordant with that previously reported 7. In a
model that included rs140068132 and rs9383938, the association
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Figure 3 | A regional plot of the  log10 P values for SNPs at 6q25.1. The
SNP with the highest  log10 P value is coloured purple and identified by its
rs no. on top of the graph. The two SNPs that were replicated in multiple
independent samples are circle-shaped, updated  log10 P values after
meta-analysis are X-shaped, and previously reported risk SNPs are triangle-
shaped. All other SNPs are represented by crosses and the colours reflect
the level of correlation with the SNP with highest  log10 P value. The LD is
estimated using data from 1,000 Genomes Project Amerindian populations.
In addition, shown are the SNP Build 37 coordinates in megabases (Mb),
recombination rates in centimorgans (cM) per megabase (Mb) and the
name and location of genes in the UCSC Genome Browser (below).
Table 1 | Discovery and replication of newly discovered
protective variants at 6q25 related to breast cancer risk in
Latinas.
6q25 Region Alleles* OR 95% CI P value MAFw
Discovery (1,497 cases/3,213 controls)
rs140068132 A/G 0.60 0.49–0.72 3 10 7 9%
rs147157845 C/A 0.59 0.48–0.72 1 10 7 9%
Replication Mexicans (977 cases/1,158 controls)
rs140068132 0.63 0.53–0.75 3 10 7 15%
rs147157845 0.66 0.55–0.78 3 106 15%
Replication Colombians (546 cases/440 controls)
rs140068132 0.54 0.41–0.71 1 10 5 10%
rs147157845 0.55 0.42–0.72 2 10 5 10%
Replication WHI Hispanics (120 cases/3,373 controls)
rs140068132 0.61 0.31–1.22 0.16 7%
rs147157845 0.60 0.30–1.19 0.15 7%
Meta-analysis (3,140 cases/8,184 controls)
rs140068132 0.60 0.53–0.67 9 10 18
rs147157845 0.61 0.54–0.68 2 10 16
CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; WHI, Women’s Health
Initiative.
*Reference allele/tested allele.
wMAF: tested allele.
8
6
4
2
0
0 1 2 3 4
Inflation factor  = 1.05
5
–Log10 (expected P)
–
Lo
g1
0 
(ob
se
rve
d 
P)
6 7
Figure 2 | Quantile–quantile plot for GWAS of breast cancer in
Latinas. The gray line represents a perfect match between the expected
distribution of –log10 P under the uniform and those observed in the
present analysis.
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between breast cancer and rs140068132 was not attenuated (OR
0.60; 95% CI 0.49–0.73).
We sequenced a 245-K region (positions 15,176,132 to
152,010,131) at 6q25 in 451 cases and 456 controls from the
MEC and did not identify any new variants (with minor allele
frequency41%) that were associated with breast cancer. We did
find three variants (rs4524618, rs9397432 and rs79692348) that
had more significant P values in the sequencing data
(Supplementary Table 4). However, when those same SNPs were
analysed in the full data set, they were less strongly associated
with breast cancer (P values 1.23 10 5, 1.25 10 5, and
7.93 10 6). Furthermore, in conditional analyses with the full
data set, they were all nonsignificant in models that included
rs140068132. In a previous admixture-mapping analysis that
included a subset of these samples, higher Indigenous American
ancestry within the 6q25 locus was associated with lower risk of
breast cancer5. Since the minor alleles of rs140068132 and
rs147157845 are protective and are only common in Latinos, we
reasoned that they are likely common in Latinos because of
Indigenous American ancestry. We checked the allele frequency
of rs140068132 in women for whom the locus-specific ancestry at
6q25 was estimated to be homozygous Indigenous American and
found the allele frequency to be 25% among controls. In contrast,
women for whom the locus-specific ancestry at 6q25 was
estimated to be homozygous European had an allele frequency
of 0.1%. Next, we used multivariate logistic regression to
determine whether the association with locus-specific ancestry
at 6q25 is attenuated after adjusting for the rs140068132
genotype. We found that after adjusting for rs140068132, the
magnitude of the log OR for local ancestry was reduced by 35%
(Table 2).
Subphenotype analyses. In analyses by oestrogen receptor (ER)
status, the associations with variants rs147157845 and
rs140068132 were stronger for ER disease versus ERþ disease
(P heterogeneity¼ 0.01; Table 3). The same trend was observed in
Colombians, for whom ER status was available for a subset of
cases (Supplementary Table 5).
We investigated the association between the rs140068132 SNP
and mammographic density in 1,113 women (304 cases and 809
controls) from the Mexican study for whom mammographic
density measures were available. In multivariate models, we found
a significant association between mammographic density and the
variants at 6q25 among the 809 controls (rs140068132 P¼ 0.001;
rs147157845 P¼ 0.005). The mean density among control
women homozygous for the rs140068132 common allele (AA)
was 16% (95% CI: 14–17%; N¼ 549), while among women
homozygous for the protective allele (GG) the mean density was
8% (95% CI: 5–12%; N¼ 29; Fig. 4). After adjusting for
Table 2 | Association between breast cancer, global
Indigenous American (IA) ancestry, local IA ancestry and
rs140068132/rs147157845*.
OR 95% CI P value
Model 1
Global IA ancestry 0.31 0.18–0.54 3.47 10 5
Model 2
Global IA ancestry 0.55 0.29–1.01 0.056
Local IA at 6q25 0.55 0.42–0.72 1.87 10 5
Model 3
Global IA ancestry 0.55 0.30–1.02 0.06
Local IA at 6q25 0.68 0.50–0.91 0.009
rs140068132 0.63 0.50–0.80 1.6 104
CI, confidence interval; IA, Indigenous American; MEC, Multiethnic Cohort; NC-BCFR, Northern
California site of the Breast Cancer Family Registry; OR, odds ratio; SFBCS, San Francisco Bay
Area Breast Cancer Study.
*These analyses included 1,476 US Latina cases and 1,131 controls from the SFBCS, the NC-BCFR
and the MEC with available locus specific ancestry estimates from a previous study.
Table 3 | Association between rs140068132/rs147157845
and breast cancer risk by ER status in US Latinas.
ER status (808 ERþ ,
293 ER , 3,221 controls)
OR* 95% CI P value
rs140068132
ERþ 0.63 0.49–0.80 1.9 104
ER 0.34 0.21–0.54 4.7 106
ER versus ERþ 0.53 0.32–0.88 0.014
rs147157845
ERþ 0.62 0.48–0.79 9.3 10 5
ER 0.34 0.21–0.54 3.8 106
ER versus ERþ 0.55 0.34–0.91 0.019
CI, confidence interval; ER, oestrogen receptor; ERþ , oestrogen receptor-positive;
ER , oestrogen receptor-negative; OR, odds ratio.
*ORs are for the minor alleles (rs140068132 allele G and rs147157845 allele A).
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Figure 4 | Box plot of percent mammographic breast density by
genotypes for SNP rs140068132 at 6q25 in 1,113 women (304 cases and
809 controls) from the Mexican study. The boxes represent the median
(black middle line) limited by the 25th (Q1) and 75th (Q3) percentiles. The
whiskers are the upper and lower adjacent values, which are the most
extreme values within Q3þ 1.5(Q3Q1) and Q1 1.5(Q3Q1),
respectively. The black dots represent outliers. N defines the number of
individuals within each genotype category.
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Figure 5 | Replication of previously reported associations in Latinas.
Scatter plot of odds ratios previously published (x axis) and in Latinas
(y axis). Red dots represent SNPs that were associated at r0.05 level of
significance in Latinas.
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mammographic breast density, the magnitude of the log OR for
the rs140068132 polymorphism on breast cancer risk was reduced
by 16% (Supplementary Table 6).
Replication of previously reported associations. We also con-
firmed the association with many of the risk variants previously
reported for breast cancer risk (Fig. 5). The allele frequencies for
these variants in Latinas were strongly correlated with frequencies
reported for European women (Supplementary Fig. 2). Twenty-
three of the eighty-three previously reported variants were asso-
ciated at Po0.05, and the majority of SNPs (84%) had ORs that
were directionally concordant with those previously reported
(Supplementary Table 3).
EMSA for rs140068132 alleles. We found evidence that
rs140068132 may be a functionally relevant variant. Rs140068132
falls within the sequence of several transcription factor-binding
sites (TFBS) in ENCODE data including FOXA1, p300, CTCF,
HA-E2F1, GATA3 and FOXA2, most of which have been impli-
cated in ER function and/or breast cancer32–36 (Supplementary
Fig. 3). Furthermore, MAPPER37 predicted the SNP to be critical
to at least four putative TFBS, three of which were disrupted with
the G versus A allele at rs140068132. To test functional relevance,
two 25-mer biotinylated probes of identical sequence except
for the A/G alleles at position chr6:151954834 were synthesized
(IDT DNA, chr6:151954823-151954847). These were designed to
encompass the four putative TFBS predicted by MAPPER.
Electrophoretic mobility shift assays (EMSA) were then
performed interrogating binding of the 25-mer probes to
nuclear protein extracts derived from MCF-7 cells, and they
demonstrated the differential binding of probes with the A versus
G allele, with far less binding of the probe containing the
protective G allele (Supplementary Fig. 4). Furthermore,
competition with an identical but unbiotinylated probe at
500-fold concentration demonstrated specificity of the
dominant-binding product.
Discussion
We performed a GWAS for breast cancer in Latinas and
identified an association between two linked variants within the
6q25 region, 50 of the ESR1 gene and breast cancer risk. The
minor allele is protective: the odds of having breast cancer
decrease by a factor of 0.60 per allele. We also found that the
minor allele is more protective against ER-negative disease and
that it is associated with decreased mammographic density. The
rs140068132/rs147157845 SNPs are relatively common in Latin
American populations, ranging between 5 and 15% depending on
the proportion of Indigenous American ancestry of the region but
are rare (o2%) or absent in other groups. These variants were
not in LD with the index variants reported in Asians and
Europeans, which suggests that the newly discovered SNPs
represent a novel signal that is specific to populations with
Indigenous American ancestry.
Previous studies have reported some risk variants at 6q25 to be
more strongly associated with ER-negative disease7,20,38. Our
findings also showed different association effect sizes by ER
status, with the rare variant at rs140068132 being more protective
for ER-negative disease. Further work will be necessary to
understand the biological mechanism behind this difference.
We have previously conducted a breast cancer admixture-
mapping analysis, which showed that higher Indigenous
American ancestry within the 6q25 locus was associated with
lower risk of breast cancer5. Adjusting for rs140068132 reduced
the magnitude of the association with local ancestry but did not
eliminate it completely. The residual locus-specific ancestry
association suggests that there may be additional rare ancestry-
informative variants associated with breast cancer at this locus
that the present study might not have detected.
High mammographic density is one of the strongest risk
factors for breast cancer. Some of the SNPs associated with breast
cancer risk have also been associated with breast density39–42,
which suggests that breast density may mediate genetic
associations. We showed that the rs140068132-protective
variant was associated with lower mammographic density and
after adjusting for mammographic breast density, the magnitude
of the log OR for the rs140068132 polymorphism on breast
cancer risk was partially reduced. This suggests that the SNP
might affect breast cancer risk both through and independently of
its effect on breast density.
We used both sequencing and in vitro assays (EMSA) to help
fine map and assess functionality. The sequence data did not
identify any novel SNP in the region that could explain the
association. Given that the rs140068132 SNP is located within the
binding site of multiple transcription factors, we conducted
EMSA assays to evaluate whether the two alleles at this position
had differential binding affinity to nuclear protein. Results clearly
showed that the protective G allele had a reduced binding affinity
to nuclear protein compared with the A allele. While our work
suggests that the A/G SNP at rs140068132 has functional
relevance, further work will be necessary to understand the exact
mechanism by which rs140068132 confers decreased breast
cancer risk.
In summary, in this GWAS of breast cancer in Latinas we
report a risk variant at the 6q25 locus that, to our knowledge,
represents the strongest association effect size on breast cancer for
a common variant reported to date. The rs140068132 variant is
limited to populations of Indigenous American ancestry,
explained at least part of the previously reported association
between breast cancer risk and genetic ancestry at the 6q25 locus
in Latinas and may partially account for the lower incidence of
breast cancer in this population. Overall, our findings highlight
the importance of conducting genetic studies in non-European
ancestry populations. Additional larger efforts in minority
populations may reveal novel variants and loci contributing to
complex traits.
Methods
Human samples. All participants provided written informed consent and the
studies were approved by local Human Subjects Committees: The Fred Hutchinson
Cancer Research Center IRB (Institutional Review Board), Comite´ de E´tica en
Investigacio´n (CEI), Ethics Committee of the University of Tolima, Cancer
Prevention Institute of California IRB, University of Southern California IRB and
the University of California San Francisco IRB.
The following studies provided samples for the discovery GWAS:
SFBCS: The SFBCS is a population-based multiethnic case–control study of
breast cancer43,44. Cases aged 35–79 years diagnosed with invasive breast cancer
from 1995 to2002 were identified through the Greater Bay Area Cancer Registry.
Controls were identified by random-digit dialing and matched on 5-year age
groups. Blood collection was initiated in 1999. The present analysis includes 351
cases and 579 controls from this study who self-identified as Latina or Hispanic.
BCFR: The BCFR is an international, National Cancer Institute (NCI)-funded
family study that has recruited and followed over 13,000 breast cancer families45.
The present study includes samples from the population-based NC-BCFR. Cases
aged 18–64 years diagnosed from 1995 to 2007 were ascertained through the
Greater Bay Area Cancer Registry. Cases with indicators of increased genetic
susceptibility (diagnosis at the age of o35 years, bilateral breast cancer with the
first diagnosis at the age of o50 years, a personal history of ovarian or childhood
cancer and a family history of breast or ovarian cancer in first-degree relatives)
were oversampled. Cases not meeting these criteria were randomly sampled46.
Population controls were identified through random-digit dialing and frequency-
matched on 5-year age groups to cases diagnosed from 1995 to 1998. We included
641 cases and 61 controls who self-identified as Latina or Hispanic from this study.
MEC: MEC is a large prospective cohort study in California (mainly Los
Angeles County) and Hawaii47. The breast cancer study is a nested case–control
study including women with invasive breast cancer diagnosed at the age of
450 years and controls matched on age and self-identified ethnicity47. For the
current study, we used data and DNA samples from 546 Latina women with breast
cancer and 558 matched Latina controls. We also included an additional 1,941
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controls who self-identified as Hispanic/Latino from this study (935 of these
controls are men).
GALA1: GALA1 is a family-based study (including children with asthma and
their parents) of pediatric asthma in Latino Americans48. The sample includes 294
individuals of Mexican origin and 365 individuals from Puerto Rico. We included
112 females of self-reported Mexican origin from the GALA1 study to our set of
population controls. The individuals are between 11 and 42 years of age (85% are
older than 20 years).
In order to replicate the top associations from the discovery GWAS, we
analysed multiple independent samples from the following studies:
The Mexico Breast Cancer Study: This study is a population-based case–control
study of breast cancer conducted in Mexico City, Monterrey and Veracruz30.
Cases aged 35–69 years diagnosed between 2005 and 2007 were recruited from
11 hospitals (three to five in each region). Controls were recruited based on
membership in the same health plan as the cases and are frequency-matched on
5-year age groups. For the current study, we used data and DNA samples from
977 women with breast cancer and 1,158 controls.
Colombian Study of Environmental and Heritable Causes of Breast Cancer
(COLUMBUS): COLUMBUS is a population-based case–control study of breast
cancer conducted in four cities: Bogota, Ibague and Neiva, from the Central
Colombian Andes region, and Pasto, from the Colombian South. Incident cases
with invasive breast cancer aged 18–75 years have been recruited in two population
registries and two large cancer hospitals. Recruitment started in 2011. Cancer-free
controls were recruited through the same institutions and were matched on
education, socioeconomic status and local origin using a genealogical interview. In
the current study, we genotyped DNA samples from 546 cases and 440 controls.
WHI SNP Health Association Resource (WHI SHARe): WHI is a long-term
national health study that focuses on understanding risk factors for common diseases
such as heart disease, cancer and fractures in postmenopausal women.
A total of 161,838 women aged 50–79 years were recruited from 40 clinical centres in
the United States between 1993 and 1998 (refs 49,50). Medical history was updated at
least annually. Breast cancers were verified by medical records and pathology report
review51,52. The WHI SHARe includes 3,493 self-identified Hispanic/Latina women
from WHI who provided consent for DNA analysis and were genotyped on the
Affymetrix 6.0 array. WHI SHARe was imputed to the 1000 Genomes Project using
MACH53. Breast cancer cases were defined as cases with incident invasive breast
cancer. We included 120 cases and 3,373 controls from this study.
Genotyping and quality-control procedures. The SFBCS, NC-BCFR and
GALA1 samples were genotyped with the Affymetrix 6.0 array according to the
manufacturer’s instructions in the Laboratory of Esteban Gonzalez Burchard
at UCSF. The MEC samples were genotyped with the Illumina Infinitum
660W-Quad or the Omni 2.5 array in the Genomics Center at USC and at the
Broad Institute (Cambridge, MA, USA).
Before imputation, we excluded 15 cases and 30 controls from the SFBCS/NC-
BCFR/GALA1 set that had a genotyping call rate o95% or showed either known
or cryptic relatedness. We excluded 26 cases and 8 controls from the MEC because
of unexpected relatedness. The final analysis included 1,497 cases and 3,213
controls (1,699 individuals from the SFBCS/NC-BCFR/GALA1 set (977 cases and
722 controls) and 3,011 from the MEC (520 cases and 2,491 controls)).
A scatter plot of the first and second principal components estimated for the US
Latina samples included in the discovery phase of the study showed the expected
distribution for this population, with most samples spreading between the
European and Asian axes (and beyond the Asian cluster towards what would be the
Indigenous American cluster) and a smaller proportion of samples deviating
towards the African cluster (Supplementary Fig. 5).
Imputation. The discovery GWAS included genotyped as well as imputed SNPs
for better coverage. Sample genotypes were phased and missing markers were
imputed using the software IMPUTE2 (ref. 54). Phased data of 1,094 samples from
the 1000 Genomes Project (www.1000genomes.org) were used as the reference data
set. These samples are from African, African American, Asian, Caucasian and
Native American populations. We excluded SNPs with an information coefficient
value o0.5 and minor allele frequency o1%. For markers in the MEC data, we
conducted additional stringent quality-control analyses to exclude SNPs with
different minor allele frequencies in controls typed on or imputed from different
genotyping platforms. SNPs that exhibited differences in minor allele frequencies
between the controls genotyped with the Illumina Infinitum 660W-Quad or Omni
2.5M platforms at Po0.01, and/or had ORs410 oro0.1 were excluded. The final
GWAS analysis included 7,229,558 SNPs.
SNP and genotyping for replication in Mexican women. SNPs were selected
for replication in an independent sample of Mexican women according to the
following criteria: (1) the polymorphic site was an SNP or captured by an SNP, as
opposed to insertion/deletion; (2) P valueo5 10 7; (3) SNPs that have not been
previously associated with breast cancer risk; and (4) when multiple SNPs were in
high LD (r240.8), one or two with the lowest P value were selected for genotyping.
A total of 14 SNPs were selected for replication. Four SNPs failed during assay
design. Genotyping for the replication of 10 SNPs was completed using Sequenom
iPLEX assays run on the MassArray Analyzer 4 platform at the University of
Minnesota Genomics Center. One SNP failed the experimental assay and was
excluded from the analysis. Each sample plate included one to three duplicates with a
replication genotyping concordance of 100%. Two SNPs had a call rate of 99.7% and
the remaining seven SNPs had a call rate of 100%. We excluded all individuals with
any missing genotypes from further analysis (six cases and six controls). The final
analysis included 977 cases and 1,158 controls. Genetic ancestry was estimated for all
Mexican samples using a previously described panel of 106 ancestry informative
markers3. These markers were genotyped with a iPLEX Sequenom assay3. Ancestry
estimation was performed with the FRAPPE55 and STRUCTURE56 programmes
including ancestral genotypes as previously described2.
Genotyping of rs140068132/rs147157845 in Colombians. Samples from
COLUMBUS were genotyped for rs140068132 and rs14757845 using the KASP
genotyping technology following the manufacturer’s instructions. Samples were
genotyped in 384-well plates that contained positive genotyping controls for the
three genotypes and two duplicates. The call rates for rs140068132 and rs14757845
were 98.0% and 98.2%, respectively. The final analyses included 546 cases and 440
controls. Association testing and meta-analyses were carried out with PLINK57.
Sequencing of 245K region in MEC study samples. We sequenced the ESR1
region at 6q25 in 451 breast cancer cases and 456 controls from MEC as part of a
multiethnic targeted sequencing project of known breast cancer GWAS loci.
Region boundaries were defined by nearest recombination hotspot downstream
and upstream from the original GWAS signal (rs2046210) as identified using the
HapMap CEU population. Briefly, 12 GWAS-identified regions covering 5,500 kb
were hybrid-captured and sequenced. Sequencing was performed at the Broad
Institute and details of the sequencing method have been described elsewhere58.
We were not able to capture 2,740 kb (48.9%) of the originally targeted sequence
primarily because of repetitive sequence content. The median proportion of
captured regions with coverage 420 was higher than 93% across all regions
(range 93.8–99.9). We used Burrows-Wheeler Aligner (BWA)59 to align reads to
the genome and GATK60,61 with default standard filters for genotype calling.
The sequence data at 6q25 encompassed 245K (positions: 151765132 to
152010131). Of a total of 4,936 variants observed, 443 had a minor allele frequency
of 40.01.
Statistical analysis. We used logistic regression models to estimate the association
between SNPs and breast cancer risk. ORs were estimated for the variant allele
based on a log-additive model and adjusted for the first 10 principal components.
PLINK version 1.06 (ref. 57) was used to analyse genome-wide data. The SFBCS,
NC-BCFR and GALA1 samples were pooled as one data set. The MEC samples
were analysed as a separate data set. Meta-analysis of the two data sets was
performed using the METAL package, which performs an inverse-variance-
weighted combination of the association effect sizes for each study and provides
P values for heterogeneity.
In order to use a systematic approach to analyse the replication of previously
reported associated variants, we decided to only include previously published SNPs
that were registered in the Catalog of Published Genome-Wide Association Studies
compiled by the National Human Genome Research Institute. In addition, we used
a restriction criteria of P value lower than 5 10 8.
Replication analyses of newly discovered variants in Mexican women,
Colombian women and in Latinas from WHI were conducted using logistic
regression models. The analysis in Mexicans was adjusted for age at diagnosis and
global genetic ancestry. For the WHI samples, genotypes for the rs140068132/
rs147157845 SNPs were available from genome-wide genotypes that were
generated as part of the WHI SHARe GWAS. The WHI analysis included
adjustment for principal components 1 to 4, region and age at diagnosis.
The Colombian samples included women from two different regions (Central
and South Colombia) who were analysed separately and were combined in a
meta-analysis using the inverse-variance method. The final meta-analysis with all
studies was conducted using the same method.
Genome-wide association analyses were performed for cases versus controls
as well as for ER-negative (ER ) and ER-positive (ERþ ) cases versus controls.
Among the MEC cases with available ER status, 303 were ERþ and 108 ER .
Of the SFBCS/NC-BCFR cases, 505 were ERþ and 185 ER . The analyses by
hormone receptor status were based on 808 ERþ and 293 ER cases (303 ERþ
and 108 ER from MEC and 505 ERþ and 185 ER from SFBCS/NC-BCFR).
We used logistic regression to evaluate the effect of global and locus-specific
ancestry on breast cancer risk when the SNPs rs140068132/rs147157845 were
included in the model. We also included the first 10 principal components, age and
study as covariates.
We used linear regression to evaluate the association between the rs140068132/
rs147157845 polymorphisms and percent breast density among controls from the
Mexican study. Percent mammographic density was log-transformed in order to
obtain a distribution that would more closely approximate normality. We included
age, body mass index, height, parity, breastfeeding, Indigenous American ancestry
and African ancestry as covariates. These analyses were conducted with the STATA
12.1 software62.
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ENCODE: The UCSC genome browser (genome.ucsc.edu) was used to get an
overview of the genetic architecture surrounding our SNPs of interest, and
specifically whether the SNPs fell within TFBSs determined by ENCODE ChIP-seq
data.
MAPPER37: MAPPER was used at default settings to interrogate Homo sapiens
sequence and bioinformatically predict putative transcription factor sites to which
our SNP was critical. We took significant putative sites to be E value o15.
Percent mammographic density measure. Percent mammographic density
measures and potential confounder variables (age at diagnosis or interview, height,
body mass index, parity and breastfeeding) were available for 1,113 (304 cases and
809 controls) women from the Mexican study. Information on covariates was
obtained by questionnaire. Mammograms from cases were collected from
participating hospitals; those from controls were performed at the same hospitals.
Craniocaudal views were digitized using an Astra 2400S scanner (Umax, Fremont,
CA, USA). A single observer measured mammographic density using Mamgr, a
computer-assisted programme developed at the Department of Epidemiology and
Population Health, London School of Hygiene and Tropical Medicine63. For cases,
the contralateral craniocaudal view was measured, and for controls the left
craniocaudal view was measured. Percent breast density was calculated by dividing
the dense area by the total breast area. The Mamgr observer was blinded to
questionnaire data. Mammographic density measurements using the Mamgr have
been compared with the Cumulus programme developed at the University of
Toronto, with a reported intraclass correlation of 0.87 (ref. 64).
Electrophoretic mobility shift assay. MCF-7 cells (ATCC) were grown in
DMEM high-glucose media with 10% fetal bovine serum in T25 flasks using
standard cell culture practices. Nuclear protein extracts were harvested from
passage 2 cells at 75% confluence and passage 3 cells at 85% confluence using the
Pierce Scientific’s NE-PER nuclear and cytoplasmic extract kit with addition of
Pierce Halt protease inhibitor cocktail. Biotinylated probes were synthesized and
high-performance liquid chromatography purified from IDT DNA. EMSA were
performed using LightShift Chemiluminescent EMSA kit (Pierce Scientific). The
control reactions were performed as suggested by the protocol, except complete
quenching of specific binding was not obtained at 200-fold concentration of
unbiotinylated competitor but was obtained at 500-fold excess competitor. The kit
protocol was followed with optimization to include the following components in
each 20ml reaction in the following order when relevant: water (variable), binding
buffer 1X, poly dI.dC 50 ng ml 1, unbiotinylated primer 10 pmol, 2 ml nuclear
protein extract and biotinylated primer 20 fmol. Preincubation of all components
was performed on ice for 2min before addition of the biotinylated primer, and all
components were then incubated for 55min at room temperature before running
the gel. Polyacrylamide gel (6%) was pre-run for 50min, run for 1 h 15min after
loading and transferred to membrane for 45min. Thereafter, crosslinking and
washes were performed as per protocol. The experiment was replicated four times,
twice each with protein derived from two different passages of MCF-7 cells, with
similar results.
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